We have a portfolio of branded products that includes established brand names such as LIDODERM®, OPANA® ER and OPANA®, PERCOCET® FROVA® and Voltaren® Gel. Branded products comprised approximately 92% of our net sales in 2007, with 65% of our net sales coming from LIDODERM. Our non-branded generic portfolio, which accounted for 8% of net sales in 2007, currently consists of products primarily focused in pain management.

We focus selectively on generics that have one or more barriers to market entry, such as complex formulation, regulatory or legal challenges or difficulty in raw material sourcing.

Through a dedicated sales force of approximately 700 sales representatives and an additional 275 contract sales representatives throughout the United States, we market our branded pharmaceutical products to high-prescribing physicians in pain management, neurology, surgery, anesthesiology, oncology and primary care. Our sales force also targets retail pharmacies and other healthcare professionals throughout the United States.

Proceed to the Company Profile